Although a number of studies have clearly pointed out that tumor angiogenesis is affected by a variety of regulatory factors, the current development and clinical application of anti-angiogenesis inhibitors are still highly focused on the strategy of targeting the signal transduction pathway mediated by VEGF and its receptor VEGFRs [215]. This evidence concerns the gene VEGFA and neoplasm.